Promoters of Colistin Resistance in Acinetobacter baumannii Infections

Elif Nurtop, Fulya Baylndlr Bilman, Sirin Menekse, Ozlem Kurt Azap, Mehmet Gonen, Onder Ergonul, Fusun Can

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: We aimed to describe the mechanisms of colistin resistance in Acinetobacter baumannii. Materials and Methods: Twenty-nine patients diagnosed with colistin-resistant A. baumannii infection were included to the study. The mutations in pmrCAB, lpxA, lpxC, and lpxD genes, expression of pmrCAB, carbapenemases, and mcr-1 positivity were studied. Results: Twenty-seven (93%) of the patients received IV colistin therapy during their stay, and the case fatality rate was 45%. All mutations in pmrC and pmrB were found to be accompanied with a mutation in lpxD. The most common mutations were I42V and L150F in pmrC (65%), E117K in lpxD (65%), and A138T in pmrB (58.6%). The colistin minimum inhibitory concentrations (MICs) of the isolates having any of these four mutations were higher than the isolates with no mutations (p < 0.001). The two most common mutations in pmrC (I42V and L150F) were found to be associated with higher expressions of pmrA and pmrC and higher colistin MIC values (p = 0.010 and 0.031). All isolates were blaOXA-23 positive. Conclusion: Coexistence of the lpxD mutation along with mutations in pmrCAB indicates synergistic function of these genes in development of colistin resistance in A. baumannii.

Original languageEnglish (US)
Pages (from-to)997-1002
Number of pages6
JournalMicrobial Drug Resistance
Volume25
Issue number7
DOIs
StatePublished - Sep 1 2019

Fingerprint

Acinetobacter Infections
Colistin
Acinetobacter baumannii
Mutation
Microbial Sensitivity Tests

Keywords

  • A. baumannii
  • colistin
  • resistance

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Pharmacology
  • Microbiology (medical)

Cite this

Nurtop, E., Baylndlr Bilman, F., Menekse, S., Kurt Azap, O., Gonen, M., Ergonul, O., & Can, F. (2019). Promoters of Colistin Resistance in Acinetobacter baumannii Infections. Microbial Drug Resistance, 25(7), 997-1002. https://doi.org/10.1089/mdr.2018.0396

Promoters of Colistin Resistance in Acinetobacter baumannii Infections. / Nurtop, Elif; Baylndlr Bilman, Fulya; Menekse, Sirin; Kurt Azap, Ozlem; Gonen, Mehmet; Ergonul, Onder; Can, Fusun.

In: Microbial Drug Resistance, Vol. 25, No. 7, 01.09.2019, p. 997-1002.

Research output: Contribution to journalArticle

Nurtop, E, Baylndlr Bilman, F, Menekse, S, Kurt Azap, O, Gonen, M, Ergonul, O & Can, F 2019, 'Promoters of Colistin Resistance in Acinetobacter baumannii Infections', Microbial Drug Resistance, vol. 25, no. 7, pp. 997-1002. https://doi.org/10.1089/mdr.2018.0396
Nurtop E, Baylndlr Bilman F, Menekse S, Kurt Azap O, Gonen M, Ergonul O et al. Promoters of Colistin Resistance in Acinetobacter baumannii Infections. Microbial Drug Resistance. 2019 Sep 1;25(7):997-1002. https://doi.org/10.1089/mdr.2018.0396
Nurtop, Elif ; Baylndlr Bilman, Fulya ; Menekse, Sirin ; Kurt Azap, Ozlem ; Gonen, Mehmet ; Ergonul, Onder ; Can, Fusun. / Promoters of Colistin Resistance in Acinetobacter baumannii Infections. In: Microbial Drug Resistance. 2019 ; Vol. 25, No. 7. pp. 997-1002.
@article{31d422d37eb6450a9ef4e0b562e06b5c,
title = "Promoters of Colistin Resistance in Acinetobacter baumannii Infections",
abstract = "Objectives: We aimed to describe the mechanisms of colistin resistance in Acinetobacter baumannii. Materials and Methods: Twenty-nine patients diagnosed with colistin-resistant A. baumannii infection were included to the study. The mutations in pmrCAB, lpxA, lpxC, and lpxD genes, expression of pmrCAB, carbapenemases, and mcr-1 positivity were studied. Results: Twenty-seven (93{\%}) of the patients received IV colistin therapy during their stay, and the case fatality rate was 45{\%}. All mutations in pmrC and pmrB were found to be accompanied with a mutation in lpxD. The most common mutations were I42V and L150F in pmrC (65{\%}), E117K in lpxD (65{\%}), and A138T in pmrB (58.6{\%}). The colistin minimum inhibitory concentrations (MICs) of the isolates having any of these four mutations were higher than the isolates with no mutations (p < 0.001). The two most common mutations in pmrC (I42V and L150F) were found to be associated with higher expressions of pmrA and pmrC and higher colistin MIC values (p = 0.010 and 0.031). All isolates were blaOXA-23 positive. Conclusion: Coexistence of the lpxD mutation along with mutations in pmrCAB indicates synergistic function of these genes in development of colistin resistance in A. baumannii.",
keywords = "A. baumannii, colistin, resistance",
author = "Elif Nurtop and {Baylndlr Bilman}, Fulya and Sirin Menekse and {Kurt Azap}, Ozlem and Mehmet Gonen and Onder Ergonul and Fusun Can",
year = "2019",
month = "9",
day = "1",
doi = "10.1089/mdr.2018.0396",
language = "English (US)",
volume = "25",
pages = "997--1002",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Promoters of Colistin Resistance in Acinetobacter baumannii Infections

AU - Nurtop, Elif

AU - Baylndlr Bilman, Fulya

AU - Menekse, Sirin

AU - Kurt Azap, Ozlem

AU - Gonen, Mehmet

AU - Ergonul, Onder

AU - Can, Fusun

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objectives: We aimed to describe the mechanisms of colistin resistance in Acinetobacter baumannii. Materials and Methods: Twenty-nine patients diagnosed with colistin-resistant A. baumannii infection were included to the study. The mutations in pmrCAB, lpxA, lpxC, and lpxD genes, expression of pmrCAB, carbapenemases, and mcr-1 positivity were studied. Results: Twenty-seven (93%) of the patients received IV colistin therapy during their stay, and the case fatality rate was 45%. All mutations in pmrC and pmrB were found to be accompanied with a mutation in lpxD. The most common mutations were I42V and L150F in pmrC (65%), E117K in lpxD (65%), and A138T in pmrB (58.6%). The colistin minimum inhibitory concentrations (MICs) of the isolates having any of these four mutations were higher than the isolates with no mutations (p < 0.001). The two most common mutations in pmrC (I42V and L150F) were found to be associated with higher expressions of pmrA and pmrC and higher colistin MIC values (p = 0.010 and 0.031). All isolates were blaOXA-23 positive. Conclusion: Coexistence of the lpxD mutation along with mutations in pmrCAB indicates synergistic function of these genes in development of colistin resistance in A. baumannii.

AB - Objectives: We aimed to describe the mechanisms of colistin resistance in Acinetobacter baumannii. Materials and Methods: Twenty-nine patients diagnosed with colistin-resistant A. baumannii infection were included to the study. The mutations in pmrCAB, lpxA, lpxC, and lpxD genes, expression of pmrCAB, carbapenemases, and mcr-1 positivity were studied. Results: Twenty-seven (93%) of the patients received IV colistin therapy during their stay, and the case fatality rate was 45%. All mutations in pmrC and pmrB were found to be accompanied with a mutation in lpxD. The most common mutations were I42V and L150F in pmrC (65%), E117K in lpxD (65%), and A138T in pmrB (58.6%). The colistin minimum inhibitory concentrations (MICs) of the isolates having any of these four mutations were higher than the isolates with no mutations (p < 0.001). The two most common mutations in pmrC (I42V and L150F) were found to be associated with higher expressions of pmrA and pmrC and higher colistin MIC values (p = 0.010 and 0.031). All isolates were blaOXA-23 positive. Conclusion: Coexistence of the lpxD mutation along with mutations in pmrCAB indicates synergistic function of these genes in development of colistin resistance in A. baumannii.

KW - A. baumannii

KW - colistin

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85070070894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070070894&partnerID=8YFLogxK

U2 - 10.1089/mdr.2018.0396

DO - 10.1089/mdr.2018.0396

M3 - Article

C2 - 30964377

AN - SCOPUS:85070070894

VL - 25

SP - 997

EP - 1002

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 7

ER -